The influence of lipid nanocapsule composition on their size distribution

被引:140
作者
Heurtault, B
Saulnier, P
Pech, B
Venier-Julienne, MC
Proust, JE
Phan-Tan-Luu, R
Benoît, JP
机构
[1] Univ Aix Marseille 3, Ctr Univ St Jerome, Lab Methodol Rech Expt, F-13397 Marseille 13, France
[2] INSERM ERIT M 0104, F-49100 Angers, France
关键词
lipid nanocapsules; size distribution; experimental mixture design;
D O I
10.1016/S0928-0987(02)00241-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A formulation process, based on the inversion phase of an emulsion, was used to prepare lipid nanocapsules. Triglycerides, lecithin, salted water and hydroxy stearate of poly(ethylene glycol) were used in the preparation. The amounts of each that allowed nanocapsules to be formed described a feasibility domain within a ternary diagram. The size distribution of various nanoparticulate carriers has already been shown to influence their applications. An experimental mixture design inside the feasibility domain has been used in order to approximate, through an empirical model, the influence of the quantitative composition of nanocapsules on their size distribution. Reduced cubic polynomial equations successfully modelled the evolution of responses in terms of particle average diameters and coefficients of variation. The results were presented using an analysis of response surface showing a scale of possible particle sizes between 20 and 95 nm and a coefficient of variation between 11 and 40%. Furthermore, this technique showed that the proportion of hydrophilic surfactant had a major influence on the average diameter and the size distribution of the particles decreasing when its proportion increased. On the contrary, the coefficient of variation and the average diameter slightly increase with the proportion of triglycerides. Such a tool offers major advantages to design the formulation of particles as a function of the required size distribution. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:55 / 61
页数:7
相关论文
共 21 条
[1]   LIPOSOME DISPOSITION INVIVO .3. DOSE AND VESICLE-SIZE EFFECTS [J].
ABRA, RM ;
HUNT, CA .
BIOCHIMICA ET BIOPHYSICA ACTA, 1981, 666 (03) :493-503
[2]   UPTAKE OF LIPOSOMES BY CULTURED MOUSE BONE-MARROW MACROPHAGES - INFLUENCE OF LIPOSOME COMPOSITION AND SIZE [J].
ALLEN, TM ;
AUSTIN, GA ;
CHONN, A ;
LIN, L ;
LEE, KC .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1061 (01) :56-64
[3]   Statistical modelling of the formulation variables in non-viral gene delivery systems [J].
Birchall, JC ;
Waterworth, CA ;
Luscombe, C ;
Parkins, DA ;
Gumbleton, M .
JOURNAL OF DRUG TARGETING, 2001, 9 (03) :169-184
[4]   Crystallization tendency and polymorphic transitions in triglyceride nanoparticles [J].
Bunjes, H ;
Westesen, K ;
Koch, MHJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 129 (1-2) :159-173
[5]   Experimental design for a pharmaceutical formulation: optimisation and robustness [J].
Campisi, B ;
Chicco, D ;
Vojnovic, D ;
Phan-Tan-Luu, R .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1998, 18 (1-2) :57-65
[6]  
CAVALLI R, 1996, EUR J PHARM BIOPHARM, V43, P110
[7]  
COX DR, 1971, BIOMETRIKA, V58, P155, DOI 10.1093/biomet/58.1.155
[8]  
GASCO MR, 1992, EUR J PHARM BIOPHARM, V68, P7
[9]   Properties of polyethylene glycol 660 12-hydroxy stearate at a triglyceride/water interface [J].
Heurtault, B ;
Saulnier, P ;
Pech, B ;
Proust, JE ;
Benoît, JP .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 242 (1-2) :167-170
[10]   A novel phase inversion-based process for the preparation of lipid nanocarriers [J].
Heurtault, B ;
Saulnier, P ;
Pech, B ;
Proust, JE ;
Benoit, JP .
PHARMACEUTICAL RESEARCH, 2002, 19 (06) :875-880